Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANB032 in Moderate to Severe Atopic Dermatitis
2023-503522-40-00Phase 2Withdrawn
- Sponsor
- AnaptysBio, Inc.
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing ANB032 with Placebo (2 arms). Primary endpoint: Change from baseline in Eczema Area and Severity Index (EASI) at Week 14. Planned start Sep 2023; status: withdrawn.
02
Drugs
ANB032
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2023-503522-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503522-40-00.